Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.

Robert F KushnerSalvatore CalannaMelanie DaviesDror DickerW Timothy GarveyBryan GoldmanIldiko LingvayMette ThomsenThomas A WaddenSean WhartonJohn P H WildingDomenica Rubino

Published in: Obesity (Silver Spring, Md.) (2020)

The STEP program evaluates the efficacy and safety of semaglutide 2.4 mg subcutaneously once weekly in a broad population. The trials will provide insights on WM in people with obesity with and without type 2 diabetes and on long-term follow-up.

Keyphrases

type diabetes
insulin resistance
metabolic syndrome
weight loss
high fat diet induced
weight gain
glycemic control
cardiovascular disease
adipose tissue
quality improvement
combination therapy